Semaglutide vs Tirzepatide for Weight Loss: What Patients Should Know
· DietsMD Editorial Team · 13 min read
Medically reviewed by DietsMD Board-Certified Physicians specializing in obesity medicine and metabolic health.
Quick Answer
Semaglutide (Wegovy®) produces an average of ~15% body weight loss. Tirzepatide (Zepbound®) produces an average of ~20–22% body weight loss by targeting both GLP-1 and GIP receptors. Both require a physician prescription and are available through online medical weight loss programs.
The question of semaglutide vs tirzepatide is one of the most common questions patients ask when exploring GLP-1 weight loss treatment. This guide provides a clinically grounded, side-by-side comparison to help you have a more informed conversation with your physician. It covers mechanisms, clinical trial data, side effects, candidacy, and how to access treatment through a physician-supervised online program.
Side-by-Side Comparison: Semaglutide vs Tirzepatide
| Feature | Semaglutide | Tirzepatide |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | GLP-1 + GIP dual receptor agonist |
| Treatment type | Once-weekly injection | Once-weekly injection |
| FDA approval (weight loss) | Wegovy® (2021) | Zepbound® (2023) |
| Avg. weight loss (trials) | ~15% body weight (STEP-1) | ~20–22% body weight (SURMOUNT-1) |
| Starting dose | 0.25 mg/week | 2.5 mg/week |
| Max approved dose | 2.4 mg/week | 15 mg/week |
| Compounded versions | Available | Available |
| Cardiovascular benefit data | SELECT trial: 20% reduction in MACE | SURMOUNT-MMO trial: ongoing |
| Common side effects | Nausea, vomiting, diarrhea, constipation | Nausea, vomiting, diarrhea, constipation |
What Is Semaglutide?
Semaglutide is a GLP-1 receptor agonist FDA-approved in 2021 as Wegovy® for chronic weight management. Learn more on our semaglutide patient guide.
How Semaglutide Works
- Appetite suppression: Reduces hunger signals in the hypothalamus
- Slowed gastric emptying: Prolongs satiety after meals
- Blood sugar regulation: Stimulates insulin and suppresses glucagon
- Reduced food cravings: May reduce reward-driven eating behaviors
Semaglutide Clinical Trial Results
- STEP-1: Adults with obesity lost an average of 14.9% of body weight over 68 weeks vs. 2.4% with placebo
- SELECT: Semaglutide reduced major adverse cardiovascular events by 20% in patients with obesity and established cardiovascular disease
What Is Tirzepatide?
Tirzepatide is a dual GIP and GLP-1 receptor agonist FDA-approved as Zepbound® for chronic weight management in 2023. Learn more on our tirzepatide patient guide.
How Tirzepatide Works
- GLP-1 agonism: Appetite suppression, slowed gastric emptying, insulin stimulation
- GIP agonism: Enhanced insulin secretion, improved fat metabolism, additional appetite regulation
- The combined effect produces greater weight loss than GLP-1 agonism alone
Tirzepatide Clinical Trial Results
- SURMOUNT-1: Adults with obesity lost an average of 20.9% of body weight at the 15 mg dose over 72 weeks — with some participants losing more than 25%
- SURMOUNT-2: Adults with obesity and type 2 diabetes lost an average of 15.7% of body weight
Key Differences Between Semaglutide and Tirzepatide
Semaglutide Strengths
- Longer track record — approved for weight loss since 2021
- Established cardiovascular benefit data (SELECT trial)
- More clinical experience and real-world data
- Often first-line for patients with cardiovascular disease
Tirzepatide Strengths
- Greater average weight loss in trials (~20–22% vs ~15%)
- Dual GIP/GLP-1 mechanism may suit patients who respond less to GLP-1 alone
- Superior glucose-lowering effects for patients with type 2 diabetes
Side Effect Profile
Both medications share a similar gastrointestinal side effect profile: nausea, vomiting, diarrhea, constipation, fatigue, and injection site reactions. Both carry the same boxed warning for thyroid C-cell tumors and are contraindicated in patients with MTC or MEN2 history.
Who May Be a Candidate?
- BMI of 30 or greater (obesity), OR
- BMI of 27 or greater with at least one weight-related condition
- No personal or family history of MTC or MEN2
- Not pregnant or planning to become pregnant
- Commitment to ongoing physician monitoring and lifestyle integration
When a Physician Might Recommend Semaglutide
- Patients with established cardiovascular disease (SELECT trial CV benefit)
- Patients who prefer a medication with a longer real-world track record
- First-line GLP-1 treatment when cost or access to tirzepatide is a barrier
When a Physician Might Recommend Tirzepatide
- Patients seeking maximum weight loss efficacy
- Patients with type 2 diabetes who may benefit from superior glucose-lowering effects
- Patients who have not achieved desired results with semaglutide
Not Sure Which Medication Is Right for You?
A DietsMD board-certified physician will review your health history and recommend the most appropriate GLP-1 treatment for your goals. Confidential. No pressure.
Why More Patients Are Exploring GLP-1 Weight Loss Treatment
Obesity Is Now Recognized as a Chronic Disease
Major medical organizations classify obesity as a chronic, relapsing disease with a strong biological basis, shifting treatment toward evidence-based pharmacotherapy.
Clinical Results That Exceed Prior Standards
Before GLP-1 medications, most weight loss pharmacotherapy produced 5–10% body weight reduction. Semaglutide and tirzepatide have more than doubled those benchmarks.
Telehealth Has Made Access Practical
Patients can now consult with board-certified physicians, receive prescriptions, and have medications delivered through online medical weight loss programs — without in-person clinic visits.
Cardiometabolic Benefits Beyond the Scale
Both medications improve blood pressure, triglycerides, HbA1c, and other cardiometabolic markers. Semaglutide has demonstrated a 20% reduction in major cardiovascular events in high-risk patients.
Start Your GLP-1 Weight Loss Journey
DietsMD connects you with board-certified physicians who specialize in semaglutide and tirzepatide programs. Discreet home delivery. Ongoing physician support.
Frequently Asked Questions: Semaglutide vs Tirzepatide
Clinical trial data shows tirzepatide produces greater average weight loss (~20-22% vs ~15%). No direct head-to-head RCT has been completed. Both are highly effective and the best choice depends on your health history and physician recommendation.
Semaglutide is a GLP-1 receptor agonist. Tirzepatide is a dual GIP and GLP-1 receptor agonist. Tirzepatide’s additional GIP activation amplifies weight loss beyond GLP-1 agonism alone. Both are once-weekly subcutaneous injections FDA-approved for chronic weight management.
Yes. Switching is possible and sometimes recommended. Any switch should be managed by a physician who can determine appropriate timing and starting dose.
Both share a similar gastrointestinal side effect profile: nausea, vomiting, diarrhea, and constipation are most common during dose escalation. Both carry the same boxed warning for thyroid C-cell tumors.
Through telehealth programs using compounded medications, semaglutide programs typically range from $200–$500/month and tirzepatide from $250–$600/month. Pricing varies by provider and dose.
Most patients notice appetite suppression within 4 to 8 weeks. Significant weight loss accumulates over 3 to 6 months. Maximum weight loss in trials was at 68 weeks (semaglutide) and 72 weeks (tirzepatide).
Clinical data shows patients who discontinue GLP-1 medications often regain significant weight within 12 months. Many physicians recommend ongoing treatment as part of a long-term weight management strategy.
Both contain semaglutide. Ozempic (up to 2 mg) is for type 2 diabetes. Wegovy (up to 2.4 mg) is for chronic weight management. The higher dose produces greater weight loss outcomes.
Both contain tirzepatide. Mounjaro is for type 2 diabetes. Zepbound is for chronic weight management. Both use the same dose range (2.5 mg to 15 mg weekly).
The right medication depends on your health history, weight loss goals, cardiovascular risk profile, tolerability, and budget. A board-certified physician specializing in obesity medicine is best positioned to evaluate your situation and recommend the most appropriate treatment.
